Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
600420.SS Stock Summary
In the News
600420.SS Financial details
Company Rating
Buy
Market Cap
11.94B
Income
860.38M
Revenue
12.4B
Book val./share
9.23
Cash/share
4.17
Dividend
0.1
Dividend %
1.06%
Employees
11.49K
Optionable
No
Shortable
Yes
Earnings
30 Mar 2024
P/E
12.99
Forward P/E
-
PEG
-
P/S
1.02
P/B
0.91
P/C
2.14
P/FCF
9.41
Quick Ratio
2.31
Current Ratio
3.04
Debt / Equity
0.09
LT Debt / Equity
0.08
-
-
EPS (TTM)
0.7
EPS next Y
-
EPS next Q
-
EPS this Y
7.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
2.9%
Revenue last 5Y
2.74%
Revenue Q/Q
-10.24%
EPS Q/Q
23.08%
-
-
-
-
SMA20
-
SMA50
-10%
SMA100
-10%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
8%
ROC
0.07%
Gross Margin
37%
Oper. Margin
9%
Profit Margin
7%
Payout
37%
Shs Outstand
1.34B
Shs Float
695.64M
-
-
-
-
Target Price
-
52W Range
7.61-14.3
52W High
-36.36%
52W Low
+27.29%
RSI
44
Rel Volume
0.93
Avg Volume
10.77M
Volume
10.01M
Perf Week
-1.66%
Perf Month
2.65%
Perf Quarter
-
Perf Half Y
-12.3%
-
-
-
-
Beta
0.218
-
-
Volatility
0.17%, 0.12%
Prev Close
1.83%
Price
8.91
Change
1.14%
600420.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 10.37 | 10.59 | 10.65 | 11.84 | 11.21 | |
Net income per share | 0.65 | 0.81 | 0.76 | 0.7 | 0.75 | |
Operating cash flow per share | 1.53 | 1.1 | 1.32 | 1.43 | 2.47 | |
Free cash flow per share | 1.16 | 0.75 | 1 | 0.98 | 2.2 | |
Cash per share | 3.4 | 4.37 | 3.05 | 3.56 | 5.26 | |
Book value per share | 6.23 | 6.59 | 6.89 | 7.3 | 8.91 | |
Tangible book value per share | 6.77 | 7.12 | 7.53 | 8.09 | 9.74 | |
Share holders equity per share | 6.23 | 6.59 | 6.89 | 7.3 | 8.91 | |
Interest debt per share | 3.61 | 3.9 | 2.77 | 3.13 | 3.04 | |
Market cap | 9.45B | 10.29B | 11.22B | 12.21B | 10.52B | |
Enterprise value | 9.35B | 9.43B | 10.64B | 11.51B | 7.78B | |
P/E ratio | 13.39 | 11.09 | 12.46 | 14.87 | 12.13 | |
Price to sales ratio | 0.83 | 0.84 | 0.89 | 0.88 | 0.81 | |
POCF ratio | 5.66 | 8.11 | 7.19 | 7.27 | 3.68 | |
PFCF ratio | 7.44 | 11.88 | 9.49 | 10.55 | 4.13 | |
P/B Ratio | 1.39 | 1.36 | 1.38 | 1.42 | 1.02 | |
PTB ratio | 1.39 | 1.36 | 1.38 | 1.42 | 1.02 | |
EV to sales | 0.83 | 0.77 | 0.85 | 0.83 | 0.6 | |
Enterprise value over EBITDA | 4 | 4.57 | 5.39 | 5.57 | 3.96 | |
EV to operating cash flow | 5.6 | 7.42 | 6.82 | 6.85 | 2.72 | |
EV to free cash flow | 7.36 | 10.88 | 9 | 9.93 | 3.05 | |
Earnings yield | 0.07 | 0.09 | 0.08 | 0.07 | 0.08 | |
Free cash flow yield | 0.13 | 0.08 | 0.11 | 0.09 | 0.24 | |
Debt to equity | 0.55 | 0.57 | 0.39 | 0.42 | 0.33 | |
Debt to assets | 0.23 | 0.24 | 0.17 | 0.19 | 0.17 | |
Net debt to EBITDA | -0.04 | -0.42 | -0.29 | -0.34 | -1.4 | |
Current ratio | 1.29 | 1.49 | 1.64 | 1.59 | 2.78 | |
Interest coverage | 5.84 | 5.44 | 8.29 | 11.29 | 9 | |
Income quality | 1.56 | 1.37 | 1.73 | 2.05 | 3.29 | |
Dividend Yield | 0.05 | 0.03 | 0.02 | 0.02 | 0.02 | |
Payout ratio | 0.65 | 0.35 | 0.23 | 0.26 | 0.21 | |
Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Research and developement to revenue | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | |
Intangibles to total assets | 0.06 | 0.06 | 0.05 | 0.04 | 0.05 | |
Capex to operating cash flow | -0.24 | -0.32 | -0.24 | -0.31 | -0.11 | |
Capex to revenue | -0.04 | -0.03 | -0.03 | -0.04 | -0.02 | |
Capex to depreciation | -0.55 | -0.56 | -0.52 | -0.64 | -0.36 | |
Stock based compensation to revenue | 0 | -0.01 | 0 | 0 | 0 | |
Graham number | 9.52 | 10.93 | 10.88 | 10.7 | 12.26 | |
ROIC | 0.1 | 0.07 | 0.08 | 0.09 | 0.06 | |
Return on tangible assets | 0.05 | 0.06 | 0.05 | 0.05 | 0.05 | |
Graham Net | -1.47 | -0.64 | -0.87 | -0.42 | 1.81 | |
Working capital | 1.9B | 3.18B | 3.97B | 4.04B | 7.49B | |
Tangible asset value | 7.39B | 8.19B | 8.88B | 9.53B | 11.26B | |
Net current asset value | 449.61M | 1.24B | 1.73B | 2.19B | 4.21B | |
Invested capital | 0.55 | 0.57 | 0.39 | 0.42 | 0.33 | |
Average receivables | 2.2B | 2.03B | 2.45B | 3.1B | 3.16B | |
Average payables | 1.67B | 1.75B | 1.85B | 1.97B | 1.57B | |
Average inventory | 2.12B | 2.32B | 2.8B | 3.18B | 2.76B | |
Days sales outstanding | 66.24 | 60.14 | 84.06 | 86.39 | 85.18 | |
Days payables outstanding | 127.98 | 87.71 | 122.39 | 79.61 | 64.66 | |
Days of inventory on hand | 145.73 | 137.85 | 180.22 | 142.89 | 110.97 | |
Receivables turnover | 5.51 | 6.07 | 4.34 | 4.23 | 4.28 | |
Payables turnover | 2.85 | 4.16 | 2.98 | 4.58 | 5.64 | |
Inventory turnover | 2.5 | 2.65 | 2.03 | 2.55 | 3.29 | |
ROE | 0.1 | 0.12 | 0.11 | 0.1 | 0.08 | |
Capex per share | -0.37 | -0.35 | -0.32 | -0.44 | -0.27 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 2.96 | 2.8 | 2.62 | 2.44 | 2.05 | |
Net income per share | 0.24 | 0.17 | 0.21 | 0.13 | 0.16 | |
Operating cash flow per share | 0.24 | 0.17 | 0.21 | 0.52 | 0.4 | |
Free cash flow per share | 0.18 | 0.12 | 0.11 | 0.48 | 0.35 | |
Cash per share | 3.83 | 5.26 | 4.08 | 4.61 | 4.17 | |
Book value per share | 7.91 | 8.91 | 8.05 | 9.71 | 9.23 | |
Tangible book value per share | 8.74 | 9.74 | 8.85 | 10.52 | 9.96 | |
Share holders equity per share | 7.91 | 8.91 | 8.05 | 9.71 | 9.23 | |
Interest debt per share | 3.28 | 2.96 | 2.04 | 0.93 | 0.86 | |
Market cap | 9.66B | 10.52B | 14.25B | 14B | 13.71B | |
Enterprise value | 8.94B | 7.78B | 11.51B | 9.34B | 9.23B | |
P/E ratio | 8.81 | 13.06 | 12.99 | 21.12 | 15.66 | |
Price to sales ratio | 2.9 | 3.25 | 4.17 | 4.62 | 5.05 | |
POCF ratio | 35.22 | 52.24 | 51.96 | 21.8 | 25.64 | |
PFCF ratio | 48.2 | 77.74 | 99.78 | 23.35 | 29.8 | |
P/B Ratio | 1.08 | 1.02 | 1.36 | 1.16 | 1.12 | |
PTB ratio | 1.08 | 1.02 | 1.36 | 1.16 | 1.12 | |
EV to sales | 2.68 | 2.4 | 3.37 | 3.08 | 3.4 | |
Enterprise value over EBITDA | 25.77 | 30.9 | 31.21 | 28.09 | 28.09 | |
EV to operating cash flow | 32.62 | 38.62 | 41.96 | 14.54 | 17.25 | |
EV to free cash flow | 44.64 | 57.46 | 80.59 | 15.57 | 20.06 | |
Earnings yield | 0.03 | 0.02 | 0.02 | 0.01 | 0.02 | |
Free cash flow yield | 0.02 | 0.01 | 0.01 | 0.04 | 0.03 | |
Debt to equity | 0.41 | 0.33 | 0.25 | 0.09 | 0.09 | |
Debt to assets | 0.2 | 0.17 | 0.14 | 0.06 | 0.06 | |
Net debt to EBITDA | -2.05 | -10.9 | -7.43 | -14.03 | -13.65 | |
Current ratio | 2.31 | 2.78 | 2.99 | 3.04 | 3.04 | |
Interest coverage | 11.83 | 10.74 | 18.26 | 14.06 | 29.9 | |
Income quality | 1 | 1 | 1 | 3.87 | 2.44 | |
Dividend Yield | 0.02 | 0.01 | 0 | 0 | 0.01 | |
Payout ratio | 0.69 | 0.33 | 0.22 | 0 | 0.88 | |
Sales general and administrative to revenue | 0.14 | -0.15 | 0.05 | -0.04 | 0.18 | |
Research and developement to revenue | 0.04 | 0.05 | 0.03 | 0.04 | 0.05 | |
Intangibles to total assets | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | |
Capex to operating cash flow | -0.27 | -0.33 | -0.48 | -0.07 | -0.14 | |
Capex to revenue | -0.02 | -0.02 | -0.04 | -0.01 | -0.03 | |
Capex to depreciation | -0.35 | -0.31 | -0.67 | -0.22 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 6.58 | 5.91 | 6.18 | 5.4 | 5.85 | |
ROIC | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Return on tangible assets | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | |
Graham Net | 0.32 | 1.81 | 1.8 | 3.29 | 2.89 | |
Working capital | 6.01B | 7.49B | 7.33B | 7.46B | 7.2B | |
Tangible asset value | 9.84B | 11.26B | 11.52B | 13.04B | 13.23B | |
Net current asset value | 2.8B | 4.21B | 4.47B | 6.13B | 5.87B | |
Invested capital | 0.41 | 0.33 | 0.25 | 0.09 | 0.09 | |
Average receivables | 3.4B | 3.14B | 3.06B | 3.01B | 2.77B | |
Average payables | 1.8B | 1.54B | 1.45B | 1.43B | 1.41B | |
Average inventory | 2.93B | 2.62B | 2.45B | 2.39B | 2.34B | |
Days sales outstanding | 87.95 | 84.01 | 81.47 | 87.03 | 86.75 | |
Days payables outstanding | 72.67 | 58.97 | 65.23 | 66.14 | 76.93 | |
Days of inventory on hand | 122.3 | 101.21 | 109.31 | 109.83 | 127.84 | |
Receivables turnover | 1.02 | 1.07 | 1.1 | 1.03 | 1.04 | |
Payables turnover | 1.24 | 1.53 | 1.38 | 1.36 | 1.17 | |
Inventory turnover | 0.74 | 0.89 | 0.82 | 0.82 | 0.7 | |
ROE | 0.03 | 0.02 | 0.03 | 0.01 | 0.02 | |
Capex per share | -0.07 | -0.06 | -0.1 | -0.03 | -0.06 |
600420.SS Frequently Asked Questions
What is Shanghai Shyndec Pharmaceutical Co., Ltd. stock symbol ?
Shanghai Shyndec Pharmaceutical Co., Ltd. is a CN stock and trading under the symbol 600420.SS
What is Shanghai Shyndec Pharmaceutical Co., Ltd. stock quote today ?
Shanghai Shyndec Pharmaceutical Co., Ltd. stock price is $8.91 today.
Is Shanghai Shyndec Pharmaceutical Co., Ltd. stock public?
Yes, Shanghai Shyndec Pharmaceutical Co., Ltd. is a publicly traded company.